Moderna has joined one of the UK’s leading pharmaceutical industry body, Association of the British Pharmaceutical Industry (ABPI) to expand its footprint and investment in the UK.
The biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines will strengthen its footprint with the new state-of-the-art vaccine research, development and manufacturing facility in the UK. It will create valuable new jobs and build on the strength of the UK’s life sciences ecosystem.
The company is best known for their work during the COVID-19 pandemic and are now developing a range of mRNA-based vaccines for a number of conditions.
The ABPI represents companies of all sizes who invest in discovering the medicines of the future, including some of the world’s largest, most innovative, and most successful pharmaceutical firms.
Darius Hughes, UK General Manager, Moderna, said: “We are delighted to join the ABPI – this alliance is an important part of our long-term commitment to the UK and supports the wider significant investments in manufacturing, research and development we are making in this country.
“Moderna is committed to delivering the greatest possible impact to people through mRNA medicines. We look forward to working with the ABPI and our fellow member companies to build on the already strong UK environment for science and innovation.”
Richard Torbett, Chief Executive, ABPI, said: “I’m delighted to welcome Moderna into membership as a world-leading pharmaceutical company that can help bring the UK closer to realising its ambitions to be a leading global centre for life sciences.
“With Moderna’s help we will be in an even stronger position to make the UK the best place in the world to research, develop and use new medicines and vaccines.”
